Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Track this carefully
Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
Participants ( N = 20) were recruited from Roanoke, VA, and surrounding areas using flyers, the internet, and word-of-mouth referrals
We mean this sincerely: any residue can interfere with the adhesive and the drug's absorption
US$ 24.47
US$ 27.79
US$ 22.44
US$ 29.81
US$ 24.04
US$ 28.70
US$ 20.97
